EP0268561A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Production and use of a novel T-cell suppressor factor
Assignee: Novartis Pharma GmbH
•
Filing: 1987-11-16
•
Granted: —
•
Expires: 2007-11-16
Abstract
Abstract Human G-TsF has been isolated in substantially pure form. Nucleic acid encoding G-TsF and its precursor peptide has been isolated, cloned and expressed in several systems. G-TsF is recovered from transformed cultures for use in several therapeutic modalities.
Inventors
- 👤 Rainer De Martin
- 👤 Adriano Section Of Clinical Immunology Fontana
- 👤 Erhard Hofer
- 👤 Renate Hofer-Warbinek
- 👤 Michael Wrann
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 21:32
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A61P; A61P17/00; A61P29/00; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61P43/00
Claims Analysis
Total Claims: 76
Claim 1
Independent Claim
10 words
A protein in substantially pure form having human G-TsF-like activity.
Claim 2
Dependent Claim
10 words
A protein in substantially pure form having human G-TsF-like activity.
Claim 3
Dependent Claim
4 words
Substantially pure human G-TsF.
Claim 4
Dependent Claim
4 words
Substantially pure human G-TsF.
Claim 5
Dependent Claim
11 words
A protein having G-TsF-like activity whenever prepared by recombinant DNA techniques.
Claim 6
Dependent Claim
11 words
A protein having G-TsF-like activity whenever prepared by recombinant DNA techniques.
Claim 7
Dependent Claim
2 words
Recombinant G-TsF.
Claim 8
Dependent Claim
2 words
Recombinant G-TsF.
Claim 9
Dependent Claim
3 words
Recombinant mammalian G-TsF.
Claim 10
Dependent Claim
3 words
Recombinant mammalian G-TsF.
Claim 11
Dependent Claim
3 words
Human recombinant G-TsF.
Claim 12
Dependent Claim
3 words
Human recombinant G-TsF.
Claim 13
Dependent Claim
3 words
Recombinant G-TsF precursor.
Claim 14
Dependent Claim
3 words
Recombinant G-TsF precursor.
Claim 15
Dependent Claim
4 words
Recombinant G-TsF precursor part.
Claim 16
Dependent Claim
4 words
Recombinant G-TsF precursor part.
Claim 17
Dependent Claim
3 words
Recombinant mature G-TsF.
Claim 18
Dependent Claim
3 words
Recombinant mature G-TsF.
Claim 19
Dependent Claim
12 words
The protein having the full amino acid sequence indicated in Fig. 2d.
Claim 20
Dependent Claim
12 words
The protein having the full amino acid sequence indicated in Fig. 2d.
Claim 21
Dependent Claim
14 words
The protein having the amino acid sequence indicated in Fig. 2d before the arrow.
Claim 22
Dependent Claim
14 words
The protein having the amino acid sequence indicated in Fig. 2d before the arrow.
Claim 23
Dependent Claim
14 words
The protein having the amino acid sequence indicated in Fig. 2d after the arrow.
Claim 24
Dependent Claim
14 words
The protein having the amino acid sequence indicated in Fig. 2d after the arrow.
Claim 25
Dependent Claim
17 words
An allelic or a variant form of a protein of any one of claims 1 to 12.
Claim 26
Dependent Claim
38 words
An allelic variant, or a variant resulting from point mutation or larger modifications to enhance activity or production without changing the main functional and structural properties, of a protein according to any one of claims 1 to 12.
Claim 27
Dependent Claim
17 words
A deletion, insertion or substitution mutant of a protein of any one of claims 1 to 12.
Claim 28
Dependent Claim
13 words
A protein of any one of claims 1 to 15 in glycosylated form
Claim 29
Dependent Claim
13 words
A protein of any one of claims 1 to 15 in non-glycosylated form.
Claim 30
Dependent Claim
13 words
A protein of any one of claims 1 to 17 in dimeric form.
Claim 31
Dependent Claim
34 words
A protein as defined in claim 10 or 12 having in amino acid position 16 from the beginning of the mature sequence Ile instead of Cys and/or in position 25 Val instead of Lys.
Claim 32
Dependent Claim
10 words
Recombinant mature G-TsF whenever prepared using the G-TsF precursor part.
Claim 33
Dependent Claim
10 words
Recombinant mature G-TsF whenever prepared using the G-TsF precursor part.
Claim 34
Dependent Claim
8 words
Mature G-TsF protein preceeded by a methionine residue.
Claim 35
Dependent Claim
8 words
Mature G-TsF protein preceeded by a methionine residue.
Claim 36
Dependent Claim
26 words
A protein of any one of claims 1 to 21 having a molecular weight for the mature monomeric unit of 12 320 daltons disregarding any glycosylation.
Claim 37
Dependent Claim
24 words
A protein of any one of claims 1 to 21 having a molecular weight for the monomeric precursor of 45 540 disregarding any glycosylation.
Claim 38
Dependent Claim
27 words
A protein of any one of claims 1 to 23 having a specific activity in the thymocyte proliferation assay of at least 5 x 10 7 units/mg.
Claim 39
Dependent Claim
32 words
A mature protein of any one of claims 1 to 24 having more than 71 % amino acid sequence similarity with the amino acid sequence indicated in Fig. 2d after the arrow.
Claim 40
Dependent Claim
30 words
A precursor protein of any one of claims 1 to 24 having more than 30 % amino acid sequence similarity with the full amino acid sequence indicated in Fig. 2d.
Claim 41
Dependent Claim
14 words
A protein of any one of claims 1 to 26 for use in therapy.
Claim 42
Dependent Claim
33 words
A process for the preparation by recombinant DNA techniques of a protein having G-TsF-like activity, comprising the recovery of expressed protein from a host cell transformed with a gene coding for such protein.
Claim 43
Dependent Claim
33 words
A process for the preparation by recombinant DNA techniques of a protein having G-TsF-like activity, comprising the recovery of expressed protein from a host cell transformed with a gene coding for such protein.
Claim 44
Dependent Claim
16 words
A process according to claim 28 for the preparation of a protein having G-TsF-like activity comprising
Claim 45
Dependent Claim
38 words
a) construction of a vector which includes nucleic acid encoding such protein, b) transformation of an heterologous host cell with the vector, c) culture of the transformed host cell and d) recovery of expressed protein from the culture.
Claim 46
Dependent Claim
38 words
a) construction of a vector which includes nucleic acid encoding such protein, b) transformation of an heterologous host cell with the vector, c) culture of the transformed host cell and d) recovery of expressed protein from the culture.
Claim 47
Dependent Claim
30 words
A process for the preparation of bioactive dimeric G-TsF via the prior synthesis of the G-TsF precursor or of parts of the G-TsF precursor essential in folding and proteolytic processing.
Claim 48
Dependent Claim
30 words
A process for the preparation of bioactive dimeric G-TsF via the prior synthesis of the G-TsF precursor or of parts of the G-TsF precursor essential in folding and proteolytic processing.
Claim 49
Dependent Claim
21 words
A process for the preparation of a protein of claim 1 or 2 comprising a cation-exchange chromatography step, preferably over Mono-S@
Claim 50
Dependent Claim
21 words
A process according to claim 31 comprising chromatography on hydroxylapatite and Pro-RPC9, cation-exchange chromatography on Mono-S@ and reversed-phase chromatography over Pro-RPC@.
Claim 51
Dependent Claim
61 words
A process according to claim 32 comprising a) concentration and diafiltration of supernatants from cells from a natural source of G-TsF such as glioblastoma cells, b) chromatography on hydroxylapatite, c) reversed-phase chromatography over using trifluoroacetic acid/acetonitrile (2 x ) as an eluant, d) cation-exchange chromatogrophy, preferably over Mono-S@, and e) reversed-phase chromatography over Pro-RPCe using trifluoroacetic acid/ 2-propanol as an eluant.
Claim 52
Dependent Claim
14 words
A cDNA coding for a protein of any one of claims 1 to 27.
Claim 53
Dependent Claim
13 words
A cDNA of claim 34 having the nucleotide sequence indicated in Fig. 2d.
Claim 54
Dependent Claim
16 words
A cDNA of claim 35 having the nucleotide sequence indicated in Fig. 2d before the arrow.
Claim 55
Dependent Claim
16 words
A cDNA of claim 35 having the nucleotide sequence indicated in Fig. 2d after the arrow.
Claim 56
Dependent Claim
39 words
A cDNA capable of hybridizing with a nucleic acid of any one of claims 34 to 37 and coding for a protein having G-TsF-like activity, or a cDNA capable of hybridizing with the complementary strand of such nucleic acid.
Claim 57
Dependent Claim
22 words
A vector for expression of a recombinant protein of any one of claims 3 to 27 including nucleic acid encoding such protein.
Claim 58
Dependent Claim
8 words
A vector of claim 39 for eucaryotic expression.
Claim 59
Dependent Claim
10 words
A vector of claim 39 for expression in CHO cells.
Claim 60
Dependent Claim
8 words
The vector of claim 39 which is p91023(B)-SUP25-1.
Claim 61
Dependent Claim
8 words
The vector of claim 39 which is pXMT3.neo7/SUP40-1.
Claim 62
Dependent Claim
8 words
A vector of claim 39 for procaryotic expression.
Claim 63
Dependent Claim
10 words
A vector of claim 39 for expression in E. coli.
Claim 64
Dependent Claim
10 words
The vector of claim 39 which is pP L SI-SUP25-1.
Claim 65
Dependent Claim
19 words
A cell line transformed with nucleic acid coding for a protein of any one of claims 3 to 27.
Claim 66
Dependent Claim
12 words
A cell line of claim 47 which is a CHO cell line.
Claim 67
Dependent Claim
10 words
The cell line of claim 47 which is CHO/ SUP40-1/10MTX.
Claim 68
Dependent Claim
22 words
A pharmaceutical composition comprising a protein of any one of claims 1 to 27 together with a pharmaceutically acceptable carrier or diluent.
Claim 69
Independent Claim
30 words
A method of treatment comprising administration of a therapeutically effective amount of a protein of any one of claims 1 to 27 to a subject in need of such treatment.
Claim 70
Dependent Claim
14 words
Use of a protein of any one of claims 1 to 27 in therapy.
Claim 71
Dependent Claim
13 words
Use according to claim 52 in immunosuppression, wound healing, bone formation, or inflammation.
Claim 72
Dependent Claim
11 words
Use according to claim 52 in organ transplant or auto-immune conditions.
Claim 73
Dependent Claim
11 words
Use according to claim 52 in osteoporosis or tissue injury conditions.
Claim 74
Dependent Claim
18 words
Use according to claim 52 in the treatment of skin lesions caused by trauma, burns, operations or senility.
Claim 75
Dependent Claim
8 words
Use according to claim 52 in cancer therapy.
Claim 76
Dependent Claim
59 words
Use of a protein of any one of claims 1 to 26, or use of a cDNA ---- of ---- any one of claims 34 to 38, or use of a vector of any one of claims 39 to 46, or use of a cell of any one of claims 47 to 49, in the preparation of G-TsF derivatives.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.